2020 ITAC-CME临床实践指南:直接口服抗凝剂时期癌症相关血栓形成的管理

2020-02-01 国际血栓形成和癌症创议 J Med Vasc. 2020 Feb;45(1):28-40.

2020年2月,国际血栓形成和癌症创议(ITAC-CME)发布了直接口服抗凝剂时期癌症相关血栓形成的管理指南。静脉血栓栓塞症(VTE)是癌症患者常见的并发症,也是癌症进展后的第二位致死原因。VTE的管理和预防在癌症患者中非常重要,但有效地治疗仍具挑战。本文主要推荐了预防和治疗癌症相关VTE的最佳方法,同时建议减少不必要或过度治疗。

中文标题:

2020 ITAC-CME临床实践指南:直接口服抗凝剂时期癌症相关血栓形成的管理

英文标题:

Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines.

发布日期:

2020-02-01

简要介绍:

2020年2月,国际血栓形成和癌症创议(ITAC-CME)发布了直接口服抗凝剂时期癌症相关血栓形成的管理指南。静脉血栓栓塞症(VTE)是癌症患者常见的并发症,也是癌症进展后的第二位致死原因。VTE的管理和预防在癌症患者中非常重要,但有效地治疗仍具挑战。本文主要推荐了预防和治疗癌症相关VTE的最佳方法,同时建议减少不必要或过度治疗。

 

拓展指南:抗凝相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2020 ITAC-CME临床实践指南:直接口服抗凝剂时期癌症相关血栓形成的管理)] GetToolGuiderByIdResponse(projectId=1, id=8d3cb1c0018685a4, title=2020 ITAC-CME临床实践指南:直接口服抗凝剂时期癌症相关血栓形成的管理, enTitle=Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines., guiderFrom=J Med Vasc. 2020 Feb;45(1):28-40., authorId=null, author=, summary=2020年2月,国际血栓形成和癌症创议(ITAC-CME)发布了直接口服抗凝剂时期癌症相关血栓形成的管理指南。静脉血栓栓塞症(VTE)是癌症患者常见的并发症,也是癌症进展后的第二位致死原因。VTE的管理和预防在癌症患者中非常重要,但有效地治疗仍具挑战。本文主要推荐了预防和治疗癌症相关VTE的最佳方法,同时建议减少不必要或过度治疗。 , cover=, journalId=null, articlesId=null, associationId=1314, associationName=国际血栓形成和癌症创议, associationIntro=, copyright=0, guiderPublishedTime=Sat Feb 01 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<P>2020年2月,国际血栓形成和癌症创议(ITAC-CME)发布了直接口服抗凝剂时期癌症相关血栓形成的管理指南。静脉血栓栓塞症(VTE)是癌症患者常见的并发症,也是癌症进展后的第二位致死原因。VTE的管理和预防在癌症患者中非常重要,但有效地治疗仍具挑战。本文主要推荐了预防和治疗癌症相关VTE的最佳方法,同时建议减少不必要或过度治疗。 </P> <P> </P>拓展指南:<strong>与<font color=red>抗凝</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=96f5e1c001850019" title="2019 ESO指南:急性脑出血口服抗凝剂逆转" target=_blank>2019 ESO指南:急性脑出血口服抗凝剂逆转</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=e58ec1c0018311fe" title="2019 多学科专家组建议:急诊室内抗凝逆转策略" target=_blank>2019 多学科专家组建议:急诊室内抗凝逆转策略</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=4965a1c001826e18" title="抗凝(栓)门诊标准操作规程专家共识" target=_blank>抗凝(栓)门诊标准操作规程专家共识</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=4aa991c001e795f9" title="2016 ISTH指南:使用直接口服抗凝剂治疗肥胖患者" target=_blank>2016 ISTH指南:使用直接口服抗凝剂治疗肥胖患者</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=25c011c001e79304" title="2016 ISTH指南:对有生育潜力的妇女直接口服抗凝血药物的管理" target=_blank>2016 ISTH指南:对有生育潜力的妇女直接口服抗凝血药物的管理</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E6%8A%97%E5%87%9D" target=_blank>有关抗凝更多指南</a></ul>, tagList=[TagDto(tagId=47707, tagName=直接口服抗凝剂), TagDto(tagId=83531, tagName=癌症相关血栓形成)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3495, appHits=77, showAppHits=0, pcHits=1466, showPcHits=2783, likes=14, shares=3, comments=3, approvalStatus=1, publishedTime=Fri Feb 28 13:47:12 CST 2020, publishedTimeString=2020-02-01, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Fri Feb 28 13:47:12 CST 2020, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 18:11:03 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2020 ITAC-CME临床实践指南:直接口服抗凝剂时期癌症相关血栓形成的管理)])
2020 ITAC-CME临床实践指南:直接口服抗凝剂时期癌症相关血栓形成的管理
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1078254, encodeId=1e4a10e8254c0, content=厉害!!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 09 01:22:02 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075331, encodeId=aa5a10e533178, content=棒棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08e55624446, createdName=ms5000001762601746, createdTime=Tue Nov 30 08:53:23 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056567, encodeId=11e5105656e2d, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:37:01 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
    2021-12-09 一己怀

    厉害!!!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1078254, encodeId=1e4a10e8254c0, content=厉害!!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 09 01:22:02 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075331, encodeId=aa5a10e533178, content=棒棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08e55624446, createdName=ms5000001762601746, createdTime=Tue Nov 30 08:53:23 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056567, encodeId=11e5105656e2d, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:37:01 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
    2021-11-30 ms5000001762601746

    棒棒

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1078254, encodeId=1e4a10e8254c0, content=厉害!!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 09 01:22:02 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075331, encodeId=aa5a10e533178, content=棒棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08e55624446, createdName=ms5000001762601746, createdTime=Tue Nov 30 08:53:23 CST 2021, time=2021-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056567, encodeId=11e5105656e2d, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Thu Sep 30 16:37:01 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
    2021-09-30 13f0c37dm61暂无昵称

    谢谢分享

    0